FutureChem Co.,Ltd
KOSDAQ 220100.KQ
FutureChem Co.,Ltd Revenue for the year ending December 31, 2023: USD 10.73 M
-
FutureChem Co.,Ltd Revenue for the year ending December 31, 2022 was USD 9.93 M, a 0.42% change year over year.
-
FutureChem Co.,Ltd Revenue for the year ending December 31, 2021 was USD 9.89 M, a -2.16% change year over year.
-
FutureChem Co.,Ltd Revenue for the year ending December 31, 2020 was USD 10.11 M, a 43.62% change year over year.
-
FutureChem Co.,Ltd Revenue for the year ending December 31, 2019 was USD 7.04 M, a 39.73% change year over year.
| Date | Revenue | Gross Profit | Operating Income | EBIT |
|---|
| CEO | Mr. Dae-Yoon Chi |
| IPO Date | Dec. 1, 2016 |
| Location | South Korea |
| Headquarters | 21, Yeonmujang 3-gil |
| Employees | 67 |
| Sector | Health Care |
| Industries | |
FutureChem Co.,Ltd produces and sells radiopharmaceuticals in Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson's disease; Alzavue, a diagnostic medicine for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303, a diagnostic PET radiopharmaceuticals for the treatment of prostate cancer; 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer's disease. FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email